TerminatedPhase 1NCT00027911
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
Studying Synovial sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Columbia University
- Principal Investigator
- Kyriakos P. Papadopoulos, MDHerbert Irving Comprehensive Cancer Center
- Intervention
- NY-ESO-1 peptide vaccine(biological)
- Eligibility
- 18 years · All sexes
- Timeline
- 2001 – 2005
Study locations (1)
- Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00027911 on ClinicalTrials.govOther trials for Synovial sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07174427Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial SarcomaTakara Bio Inc.
- RECRUITINGPHASE1NCT06946225ACTengine® IMA203 Combined With mRNA-4203Immatics US, Inc.
- RECRUITINGNCT05910307Synovial Sarcoma Registry / Biospecimen RepositoryChildren's Hospital of Philadelphia